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Abstract
Objectives This study evaluates the risk of cardiovascular disease (CVD) following breast cancer, accounting for baseline 
CVD risk.
Methods Within the EPIC-NL (Dutch part of the European Prospective Investigation into Nutrition and Cancer) cohort, 1103 
women were diagnosed with breast cancer. For every breast cancer patient, 3–4 women without breast cancer (n = 4328) were 
selected matched for age, year, and time since cohort enrollment. Based on CVD risk factors at cohort enrollment, 10-year 
risk of CVD was calculated and categorized: low (< 10%), intermediate (10–20%), high (> 20%). Cox proportional hazard 
models assessed the risk of CVD events (hospitalization or mortality) and CVD mortality of women with versus without 
breast cancer, adjusted for baseline CVD risk.
Results After median follow-up of 5 and 6 years, 92 (8.3%) and 325 (7.5%) CVD events occurred in women with and without 
breast cancer, respectively. In the low CVD risk group, women with breast cancer had 1.44 (95% CI 1.00–2.06) times higher 
risk of CVD events than women without breast cancer. In the intermediate and high CVD risk categories, risk of CVD events 
was similar in women with and without breast cancer. Overall, women with breast cancer had 1.77 (95% CI 1.10–2.86) times 
higher risk of CVD mortality than women without breast cancer.
Conclusions Among women with low CVD risk, women with breast cancer have a higher risk of CVD event than women 
without breast cancer. Overall, women with breast cancer have a higher risk of CVD mortality than women without breast 
cancer.
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Introduction
Breast cancer incidence and survival are high in developed 
countries [1]. Survival has substantially improved due to 
early detection by screening programs and improved treat-
ments [2–4]. This has resulted in over 3 million 5-year 
breast cancer survivors worldwide [1]. Many of these 
women will die of conditions other than breast cancer [5, 
6]. Cardiovascular disease (CVD) is an important cause 
of death in the general population, also following breast 
cancer with 24% of patients over 65 years die of this dis-
ease [7, 8].
Breast cancer patients may have a higher CVD risk 
compared to the general population. Although cancer treat-
ments such as anthracycline-based regimens, trastuzumab, 
and radiotherapy reduce the risk of cancer recurrence and 
death, they have been associated with an increased risk 
of CVD [9–16]. Anthracycline-based chemotherapy and 
trastuzumab increase the risk of heart failure by fivefold 
compared to regimens without these components [17, 
18]. Furthermore, radiotherapy increases the risk of death 
from circulatory disease with 25% [11]. Another reason 
that breast cancer patients may have a higher CVD risk is 
because risk factors for both diseases overlap, especially 
risk factors as obesity and physical inactivity [19]. Breast 
cancer patients may have a higher prevalence of CVD risk 
factors than the general population. Pre-existing CVD risk 
factors have also been associated with a higher risk of 
cancer treatment-induced cardiotoxicity [20, 21].
Except for a few studies [7, 22, 23], the majority did not 
adjust for traditional CVD risk factors when investigating 
the risk of CVD following breast cancer. The Framingham 
risk score is a composite score based on traditional CVD 
risk factors (age, sex, current smoking, diabetes, and high 
systolic blood pressure) to predict the absolute 10-year 
baseline CVD risk [24]. The current study assessed the 
risk of CVD for women with breast cancer, compared 
to women without breast cancer, with a low (< 10%), 
intermediate (10–20%), and high (> 20%) baseline risk 
of CVD. Next, we assessed the risk of death from CVD 
adjusted for the baseline CVD risk.
Methods and materials
Study design and population
The current study included women participating in the 
Dutch contribution to the European Prospective Investiga-
tion into Cancer and Nutrition (EPIC-NL), which consists 
of the MORGEN and Prospect cohorts [25]. Details on 
the design and rationale of the EPIC-NL study have been 
described elsewhere [26]. Briefly, prospect is a prospec-
tive cohort study that was set up to investigate the role of 
nutrition and biomarkers in the etiology of cancer. The 
MORGEN cohort was set up to monitor risk factors for 
chronic diseases in the Netherlands. MORGEN includes 
22,654 men (45%) and women aged 20–64 years residing 
in three Dutch towns (Amsterdam, Doetinchem, and Maas-
tricht) between 1993 and 1997 [27]. Prospect includes 
17,357 women aged 49–70 living in the city of Utrecht 
or its vicinity who participated in the nationwide Dutch 
breast cancer screening program between 1993 and 1997 
[28]. The ethics committees of the respective institutions 
approved both studies, and all participants gave their writ-
ten informed consent.
Women with prevalent cancer at EPIC-NL enrolment (t0) 
were not eligible for the current study. Furthermore, women 
were not included if they had not given consent for linkage 
with vital status or morbidity registries (n = 2717) or had 
missing information on hospital admission or cause of death 
(n = 55). The current study included all women diagnosed 
with a first in situ or invasive breast cancer during follow-up 
in the EPIC-NL cohort until December 31, 2010 (referred to 
as ‘exposed’ in the current study). Subsequently four women 
without breast cancer during follow-up were matched to the 
exposed women on age at breast cancer diagnosis (t1), year 
of breast cancer diagnosis (t1), and time between EPIC-NL 
enrolment (t0) and breast cancer diagnosis (t1) (the ‘unex-
posed’ group). We would like to stress that this is not a 
matched case–control study, but rather a prospective follow-
up study, matched on the exposure status (breast cancer).
The final study population consisted of 1103 women diag-
nosed with breast cancer and 4328 women without breast 
cancer.
Exposure (breast cancer) assessment
In situ or invasive breast cancers in the EPIC-NL study were 
identified through regular linkages to the Dutch Cancer Reg-
istry. Details on the registry linkage have been described 
elsewhere [26]. Briefly, the Dutch Cancer Registry identi-
fies incident cancer cases by hospital records and is 95% 
complete since 1989.
Characteristics
At t0, a general questionnaire was filled out by all partici-
pants including questions on demographic characteristics, 
presence of chronic diseases, and risk factors for chronic dis-
eases. Educational level was categorized into low (primary 
school and lower vocational education) and other (advanced 
elementary education, intermediate vocational education, 
higher general secondary education, higher vocational 
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education, and university). Diabetes was present if partici-
pants were diagnosed with diabetes according to the general 
questionnaire. Physical activity was assessed by questions 
on occupational and recreational physical activity during the 
past year at t0 [29]. The Cambridge Physical Activity Index 
combined these activities and categorized them into active, 
moderately active, moderately inactive, and inactive [30, 
31]. Smoking behavior was categorized into current, former, 
or never. Alcohol consumption (gram ethanol per day) was 
assessed with a validated Food Frequency Questionnaire at 
t0 [32, 33]. The body mass index was calculated as weight 
divided by height squared (kg/m2), which were measured 
during physical examination. At this contact, blood pressure 
was measured twice in supine position on the left arm using 
a random zero sphygmomanometer (MORGEN) and on the 
right arm using a Boso Oscillomat (Prospect), from which 
the mean was taken. The comparability of both measure-
ment procedures is reported in more detail elsewhere [34]. 
In MORGEN, serum cholesterol levels were assessed from 
ethylene–diamine–tetra–acetic acid (EDTA) serum samples 
drawn during physical examination at t0 using an enzymatic 
method [26]. In Prospect, cholesterol values are measured 
with EDTA using serum samples and/or with citrate plasma.
History of CVD before t1 was determined by combin-
ing data from the general questionnaire at t0 and data from 
the Dutch Centre for Health Care Information on hospital 
discharge diagnosis. The Dutch Centre for Health Care 
Information holds a standardized computerized register of 
hospital discharge diagnoses coded according to the Inter-
national Classification of Diseases, Ninth Revision, Clinical 
Modification (ICD-9).
Framingham risk score
The Framingham risk score was calculated for the total 
study population based on the following characteristics 
at t0 (median of 8 years before breast cancer diagnosis or 
reference date): age, smoking behavior (current or past/
never), diabetes (presence or absence), systolic blood pres-
sure (mmHg), total cholesterol (mmol/L), and high-density 
lipoprotein (HDL) cholesterol (mmol/L) [24]. The Framing-
ham risk score ranges from −2 to 21, indicating a 10-year 
absolute risk of developing CVD and risk of individual CVD 
events (hospitalization or death) of less than 1% to over 30%, 
respectively. The current study categorized the Framing-
ham risk score into three categories: low (score: < 13, 
risk: < 10%), intermediate (score: 13–17, risk: 10–20%), 
high (score: > 17, risk: > 20%).
Outcome assessment
The outcomes were a CVD event, defined as a hospitaliza-
tion for CVD or death from CVD, and death from CVD. 
Follow-up data on the outcomes were complete until Decem-
ber 31, 2010. Follow-up data on CVD hospitalizations were 
obtained from the Dutch Centre for Health Care Informa-
tion. The database was linked to the cohort on the basis 
of birth date, gender, postal code, and general practitioner 
with a validated probabilistic method [35]. Causes of death 
were obtained from the Statistics Netherlands and have been 
coded according to the Ninth Revision of the International 
Classification of Diseases (ICD-9) until 1996, and after that, 
according to the Tenth Revision of the International Statisti-
cal Classification of Diseases (ICD-10). Death from CVD 
was based on primary and secondary causes of death. The 
primary cause of death is defined as the underlying disease 
that led to death. The secondary cause of death is either a 
complication of the primary cause, or another disease which 
might have contributed to the death.
Data analyses
Multiple imputation of missing values was performed using 
20 imputed datasets to deal with missing values of demo-
graphics and cardiovascular risk factors at t0 [36]. In the 
current study, determinants with missing values were educa-
tional level (n = 16, 0.3%), smoking behavior (n = 4, 0.1%), 
diabetes (n = 6, 0.1%), systolic blood pressure (n = 21, 
0.4%), total cholesterol (n = 289, 5.3%), HDL cholesterol 
(n = 296, 5.5%), alcohol consumption (n = 16, 0.3%), and 
body mass index (n = 6, 0.1%).
Means [standard deviation (SD)] and medians [interquar-
tile range (IQR)] were used to describe continuous variables 
with and without normally distributed data, respectively. 
Time at risk started at t1 and ended at the date of a CVD 
event (primary outcome) or date of death from CVD (sec-
ondary outcome), death from any other cause, end of study 
(December 31, 2010), or loss to follow-up (n = 29), which-
ever occurred first. Cox proportional hazard models [37] 
were used to estimate (adjusted) hazard ratios (HR) and 95% 
confidence intervals, comparing women with breast cancer 
to women without breast cancer. In addition, a competing 
risk analysis [38] was performed to deal with breast cancer 
as a competing risk: here the HR estimated by the Fine-Gray 
model account for the fact that women who died of breast 
cancer are no longer eligible of experiencing the event of 
interest.
The analyses on the risk of a CVD event (hospitalization 
or death due to CVD) were performed for the total study 
population and stratified by low (< 10%), intermediate 
(10–20%), or high (> 20%) Framingham risk category. The 
analysis including the total study population was adjusted for 
Framingham risk score and body mass index. The analysis 
stratified by Framingham risk category was adjusted for age 
at t1, i.e., the stratification by Framingham risk created new 
groups and therefore women within these groups were no 
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longer age-matched, and body mass. The analysis on the 
risk of death from CVD was performed only for the total 
study population and adjusted for Framingham risk score; 
the low number of deaths did not allow for stratification by 
Framingham risk category. In addition, a sensitivity analysis 
was performed excluding women with a history of CVD to 
test the hypothesis that women with a known risk of CVD 
at breast cancer diagnosis receive less cardiac toxic breast 
cancer treatments.
Statistical analyses were conducted using IBM SPSS sta-
tistics version 23, except for the competing risk analyses 
which were conducted with SAS version 9.4.
Results
At EPIC-NL cohort enrolment (t0), median age of the study 
population was 54 years (IQR = 50–60) for women with 
breast cancer and women without breast cancer (Table 1). 
At t0, median Framingham risk score was not different for 
women who would develop breast cancer (13, IQR = 9–16) 
than for women who would not develop breast cancer (12, 
IQR = 9–16) (Table 1). The majority of women with and 
without breast cancer were in the low Framingham risk cat-
egory: 61.3 and 66.0%, respectively. The mean body mass 
index at t0 was comparable for women with and without 
breast cancer in the low Framingham risk category: 25.2 
(SD = 3.7) and 25.1 (SD = 3.8), respectively (Supplemental 
material Table A). In the intermediate and high Framingham 
risk categories, the mean body index was also comparable 
between women with breast cancer (27.3 (SD = 4.2) and 
28.5 (SD = 3.8), respectively) and without breast cancer 
(27.2 (SD = 4.2) and 28.1 (SD = 4.5), respectively).
Breast cancer patients had 5 years (IQR = 2–9) median 
follow-up (since t1) and this was 6 years (IQR = 3–10) for 
women without breast cancer (Table 1). During this period, 
72 women with breast cancer (6.5%) and 290 without breast 
cancer (6.7%) were hospitalized for CVD (Table 2). Hospi-
talizations for acute pulmonary heart disease and heart fail-
ure were more common in women with breast cancer than 
in women without breast cancer. There were 24 women with 
breast cancer (2.2%) and 57 women without breast cancer 
(1.3%) who died of CVD as primary or secondary cause. 
Coronary heart disease and cerebrovascular accident were 
the most common causes of death from CVD in both groups. 
Death from breast cancer was the most prevalent cause of 
death among women with breast cancer (n = 115, 10.4%).
The risk of a CVD event (hospitalization or death due to 
CVD) did not differ between women with breast cancer and 
women without breast cancer: adjusted HR = 1.16 (95% CI 
0.92–1.47) (Table 3). However, in the low Framingham risk 
category the risk of a CVD event was higher in women with 
breast cancer than in women without breast cancer: adjusted 
HR = 1.44 (95% CI 1.00–2.06). Excluding women with a 
history of CVD slightly increased this risk (Supplemental 
material Table B). Furthermore, in the total study popula-
tion, the risk of death from CVD was higher in women with 
breast cancer than in women without breast cancer: adjusted 
HR = 1.77 (95% CI 1.10–2.86). The competing risk analyses 
did not change the interpretation of the results described 
above (Supplemental material Table C).
Discussion
The results of this study indicate that the risk of a CVD 
event (hospitalization or death) among women with a low 
Framingham risk (< 10%) is 44% higher in women with 
breast cancer compared to women without breast cancer. 
No difference was observed in the total study population. 
We did find that women with breast cancer have an adjusted 
77% higher risk of death from CVD than women without 
breast cancer.
Although breast cancer is the main cause of death in 
women with breast cancer, CVD is increasingly recognized 
as an important contributor to mortality in breast cancer 
survivors [39–41]. CVD may be related to cardiac toxic or 
metabolic effects of some breast cancer treatments such as 
trastuzumab, anthracycline-based regimens, and radiother-
apy [9, 42–44].
Several CVD disorders may contribute to a higher CVD 
risk following breast cancer. Women with breast cancer in 
the low Framingham risk category were more often hospi-
talized with heart failure or acute pulmonary heart disease 
than low-risk women without breast cancer. Heart failure 
is a known complication induced by anthracycline-based 
chemotherapies, trastuzumab, and radiotherapy-induced 
cardiomyopathy due to coronary artery calcifications caused 
by high radiotherapy heart dose [45–47]. Acute pulmonary 
heart disease can be caused by vascular changes as a result 
of tissue damage due to radiotherapy, as part of the lungs 
is irradiated [48]. Both heart failure and radiation-induced 
pulmonary damage may become evident during the first 
year after treatment or later [48, 49]. We also observed that 
women with breast cancer died more often due to a cerebro-
vascular accident. Women who received hormonal treatment 
(tamoxifen) had a 90% higher risk of a cerebrovascular acci-
dent [50]. Studies reported conflicting results on the associa-
tion between cerebrovascular accident and radiotherapy to 
the supraclavicular lymph nodes: Nilsson et al. [51] found 
a 12% higher risk for women with a history of breast can-
cer, while Hooning et al. [21] did not found a higher risk in 
women with breast cancer [50, 51].
A study that stratified women by CVD risk at breast 
cancer diagnosis showed that in the low CVD risk group, 
women treated with radiotherapy were not at increased risk 
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of CVD [52]. However, CVD risk was increased for women 
with an intermediate or high CVD risk [52]. These results 
are, however, difficult to compare with ours as a comparison 
with women without breast cancer is lacking. Our finding 
of a higher risk of CVD death in women with breast cancer 
is in line with many other studies [7, 39, 53, 54]. Riihi-
maki et al. showed that women with breast cancer have a 
1.29 time higher risk of dying of heart failure [53]. They 
did, however, not correct for CVD risk factors other than 
age. Bradshaw et al. reported a 1.9 times increased risk of 
Table 1  Characteristics of 1103 
women with breast cancer and 
4328 matched women without 
breast cancer at time of original 
cohort (EPIC-NL) enrolment 
(t0) and at time of breast cancer 
diagnosis or reference (t1)
Women were matched by (1) age at original cohort enrolment (t0) and (2) time between original cohort 
enrolment and breast cancer diagnosis (t1–t0)
IQR interquartile range, SD standard deviation
a Low educational level: lower vocational training or primary school
b Framingham risk score is based on age at original cohort enrolment, smoking behavior, diabetes, systolic 
blood pressure, and total and HDL cholesterol
Women with breast 
cancer
Women 
without breast 
cancer
n = 1103 n = 4328
At time of original cohort enrolment (t0)
 Original cohort, % (n)
  Prospect 70.4 (776) 68.9 (2984)
  MORGEN 29.6 (327) 31.1 (1344)
 Age at t0, year, median (IQR) 54 (50–60) 54 (50–60)
 Low education, % (n)a 45.2 (499) 43.9 (1898)
 Physical activity, % (n)
  Inactive 8.2 (90) 6.2 (270)
  Moderately inactive 26.5 (292) 25.0 (1080)
  Moderately active 25.7 (284) 27.1 (1174)
  Active 39.6 (437) 41.7 (1804)
 Smoking behavior, % (n)
  Current 25.5 (281) 24.7 (1069)
  Former 36.2 (400) 32.6 (1413)
  Never 38.3 (422) 42.7 (1846)
 Alcohol consumption, g/day, mean (SD) 10.3 (13.7) 9.1 (12.4)
 Diabetes, % (n) 2.4 (27) 2.0 (86)
 Systolic blood pressure, mmHg, mean (SD) 130.8 (20.3) 128.6 (20.0)
 Total cholesterol, mmol/L, mean (SD) 5.9 (1.1) 5.9 (1.1)
 HDL cholesterol, mmol/L, mean (SD) 1.5 (0.4) 1.5 (0.4)
 Body mass index, kg/m2, mean (SD) 25.7 (4.1) 25.2 (4.1)
 Framingham risk score, median (IQR)b 13 (9–16) 12 (9–16)
 Framingham risk categories, % (n)b
  < 10% 61.3 (676) 66.0 (2856)
  10–20% 29.1 (321) 26.1 (1131)
  20% 9.6 (106) 7.9 (341)
At time of breast cancer diagnosis or reference (t1)
 Age at t1, year, median (IQR) 63 (56–68) 63 (56–68)
 Calendar year of t1, A2
  1993–1999 26.7 (294) 26.6 (1153)
  2000–2005 38.3 (422) 38.3 (1658)
  2006–2010 35.1 (387) 35.1 (1517)
 History of cardiovascular disease at t1, % (n) 68 (6.2) 219 (5.1)
 Time between t0 and t1, year, median (IQR) 8 (4–11) 8 (4–11)
 Follow-up time since t1 (until end of study), year, median 
(IQR)
5 (2–9) 6 (3–10)
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CVD death in women with breast cancer, after adjustment 
for traditional CVD risk factors [7]. This risk manifested 
approximately 7 years after diagnosis. Furthermore, studies 
have found increased risk of CVD events up to and beyond 
20 years after diagnosis [8, 9, 55]. Age is a well-known CVD 
risk factor [56] and cardiac toxicity induced by radiotherapy 
manifest itself many years following treatment [15, 57]. As 
the current study has a relative short follow-up time (median 
of 5–6 years), this may indicate that the risk of death from 
CVD in breast cancer patients may become larger over time.
There is also a suggestive clarification for the observa-
tions in our study. The sensitivity analysis shows that the 
risk of a CVD event in women with breast cancer with a 
low Framingham risk score was higher when women with 
a history of CVD were excluded. This may indicate that in 
clinical practice women with a higher CVD risk, i.e., his-
tory of CVD, receive less cardiac toxic cancer treatments 
than women without a higher CVD risk [58]. As such, 
women with breast cancer in the low Framingham risk cat-
egory may have received more often systemic therapy, i.e., 
anthracyclines and trastuzumab, and radiotherapy (includ-
ing differences in laterality of the irradiated breast and tar-
geted volumes) than women with an intermediate or high 
Framingham risk. Unfortunately, we were not able to test 
other hypotheses related to breast cancer treatment and char-
acteristics as this information is missing for over one-third 
of patients.
We were not able to account for changes in CVD risk 
factors after EPIC enrolment. We assume that these factors 
used for calculating the Framingham risk score remained 
more or less similar until time of breast cancer diagnosis 
(t1) and thereafter. However, CVD risk factors may have 
changed between t0 and t1 (median time of 8 years) and 
after t0. This would result in women shifting to another 
Framingham risk category. It Is unclear how this would 
affect our results. Another concern is that we likely have 
missed women with CVD. The use of hospital discharge 
registry underestimates the true incidence rates, espe-
cially for coronary heart disease and heart failure [59]. 
This underestimation is most likely nondifferential and 
Table 2  Cardiovascular disease hospitalization and/or death and other causes of death in 1103 women with breast cancer and 4328 matched 
women until December 31, 2010
Numbers may overlap as women with CVD morbidity may have died of CVD (n = 4 or n = 22 for women with or without breast cancer, respec-
tively) or due to another cause
Women were matched by (1) age at original cohort enrolment (t0) and (2) time between original cohort enrolment and breast cancer diagnosis 
(t1–t0)
CVD cardiovascular disease, ICD international classification of diseases
a Primary and/or secondary CVD causes of death. 9 women with breast cancer and 8 women without breast cancer died of CVD as secondary 
cause of death
ICD-9 ICD-10 Women with 
breast cancer [% 
(n)]
Women without 
breast cancer [% 
(n)]
Hospitalization for CVD 6.5 (72) 6.7 (290)
 Coronary heart disease 410–414, 427.5, 798.1, 798.2, 
798.9
I20–I25, I46, R96 2.5 (28) 3.2 (137)
 Cerebrovascular accident 430–434, 436 I60–I67, I69, G45 1.1 (12) 2.1 (89)
 Acute pulmonary heart disease 415 I27 1.3 (14) 0.3 (12)
 Heart failure 428 I50 0.8 (9) 0.5 (22)
 Arterial embolism and throm-
bosis
444 I74 0.3 (3) 0.3 (11)
 Other 440–443 I70–I73 0.5 (6) 0.4 (19)
Death from  CVDa 2.2 (24) 1.3 (57)
 Coronary heart disease 410–414, 427.5, 798.1, 798.2, 
798.9
I20–I25, I46, R96 0.4 (4) 0.5 (23)
 Cerebrovascular accident 430–438 I60–I67, I69, G45 0.7 (8) 0.4 (16)
 Other 401, 415, 417, 424.1, 424.2, 424.9, 
425, 427.3, 427.9, 428, 440, 441, 
456
I10, I26, I27, I35, I36, I38, I48, 
I49.9, I50, I70, I71, I85
1.1 (12) 0.4 (18)
Primary cause of death other than CVD  14.6 (161) 3.0 (170)
 Breast cancer 174 C50 10.4 (115) 0.0 (0)
 Other type of cancer 140–173, 175–232, 234–239 C00–C49, C51–C97, D00–D49 2.6 (29) 2.3 (98)
 Other All other codes All other codes 1.5 (17) 1.6 (72)
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therefore not creating bias, as it can be expected that the 
underestimated incidences are not different for women 
with breast cancer than for women without breast cancer.
To conclude, this study shows that among women with 
a low Framingham risk, women with breast cancer have 
a higher risk of a CVD event (hospitalization or death) 
than women without breast cancer. Overall, women with 
breast cancer have a higher risk of death from CVD than 
women without breast cancer adjusted for Framingham 
risk score. Future research may investigate an individual-
ized approach for breast cancer patients to optimize the 
balance between high breast cancer tumor control and 
minimal cancer treatment-induced CVD risk.
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adjusted for age at breast cancer diagnosis or reference (age at t1)
d Models including the total study population are adjusted for Framingham risk score and body mass index. Models stratified by Framingham risk 
category are adjusted for age at breast cancer diagnosis or reference (age at t1) and body mass index
Num-
ber of 
women
Total PY Number of CVD (%)a Number of 
CVD per 100 
PY
Unadjusted  HRb Adjusted  HRb,c Adjusted  HRb,d
CVD event (hospitalization or death)
 Total study population (n = 5431)
  Women without breast 
cancer
4328 28,035 325 (7.5) 1.2 1 1 1
  Women with breast 
cancer
1103 6401 92 (8.3) 1.4 1.23 (0.97–1.55) 1.17 (0.92–1.57) 1.16 (0.92–1.47)
 Framingham risk < 10% (n = 3532)
  Women without breast 
cancer
2856 18,518 129 (4.5) 0.7 1 1 1
  Women with breast 
cancer
676 3783 39 (5.8) 1 1.45 (1.01–2.07) 1.45 (1.01–2.08) 1.44 (1.00–2.06)
 Framingham risk 10–20% (n = 1452) 
  Women without breast 
cancer
1131 7187 124 (10.9) 1.7 1 1 1
  Women with breast 
cancer
321 2031 30 (9.3) 1.5 0.86 (0.57–1.29) 0.88 (0.59–1.32) 0.88 (0.59–1.32)
 Framingham risk > 20% (n = 447)
  Women without breast 
cancer
341 2287 68 (19.9) 3 1 1 1
  Women with breast 
cancer
106 584 23 (21.7) 3.9 1.27 (0.78–2.07) 1.27 (0.78–2.07) 1.27 (0.78–2.06)
 Death from CVD
 Total study population (n = 5431) 
  Women without breast 
cancer
4328 29,207 57 (1.3) 0.2 1 1 –
  Women with breast 
cancer
1103 6717 24 (2.2) 0.4 1.88 (1.16–3.03) 1.77 (1.10–2.86)
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